Tempus AI announced multi-year, strategic collaborations with AstraZeneca and Pathos AI, Inc., aimed at building a multimodal foundation model in oncology. This model will be used to gather biological and clinical insights, discover novel drug targets, and develop therapeutics for the broader oncology community.
The agreements include $200 million in data licensing and model development fees payable to Tempus. Tempus’ de-identified oncology data will be utilized to construct the foundation model, which, upon completion, will be shared among all three parties to advance their individual efforts to improve patient care.
This collaboration expands on a strategic partnership between Tempus and AstraZeneca initiated in 2021. Tempus CEO Eric Lefkofsky stated that generative AI and large multimodal models are the final catalyst needed to usher in precision medicine in oncology at scale, leveraging Tempus's decade-long investment in collecting necessary data for such a foundation model.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.